In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing’s disease. Lastly, we review claims data to identify the trends for use of Dupixent®.
For more information about a topic, please contact Janelle Sheen, Karen Powell or Mary-Beth Plum. Be sure to watch for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.
Other content in this Stream

How Major Healthcare Payers are Automating Open Enrollment
Advanced digital capabilities take the stress out of the busiest time of the year

June 2020 Clinical Watch Newsletter
In this issue of Clinical Watch, we discuss nitrosamine impurities found in widely used medications and suggest prior authorization criteria for a new treatment for heavy menstrual bleeding

May 2020 Clinical Watch Newsletter
In this issue of Clinical Watch, we highlight the use of diabetes drugs in the treatment of heart failure and suggest prior authorization criteria for the first approved treatment of plexiform neurofi

Health disparities are front and center now. Where do we go from here?
Public health professionals have been sounding the alarm for years, but the COVID-19 pandemic and the sweeping protests following the death of George Floyd have brought the message front and center